spacer
home > ebr > summer 2016 > less is more
PUBLICATIONS
European Biopharmaceutical Review

Less is More

A recent Washington Post article ran with the title ‘Specialty drugs now cost more than median household income’. Medical costs are in the spotlight, and drug prices in particular garner the most attention. In a system where 80% of medical costs are affected by physician decisions, doctors are under increased pressure to balance patient needs against limited resources. The high price of speciality cancer drugs places the disparate interests of patient and payer into sharp focus.

New game-changing therapies seek to ‘cure’ certain serious or hereditary disorders, rather than treat them chronically. Gene therapy and cancer vaccines are a harbinger of the future. They are at once enormously expensive, and replace a lifetime of chronic care and dosing with a single curative regimen.

Success has considerable merit. Clearly, they promise to alleviate patient burden and suffering, while reducing medical resource utilisation. The missing links are business models and policy mechanisms to align the stakeholders on the high upfront cost of treatment, versus the long tail of future savings.

New therapies can be expensive. They entail the high production costs inherent in biologics. There are also technical barriers like immunogenicity, delivery system, specificity and duration. Payers and innovators together will need to resolve basic market issues: market size; clinical efficacy; comparative effectiveness; and overall budget impact. Even if it works, there are the regulatory issues: how long is the clinical trial? Should patients be enrolled by phenotype or genotype? What biomarker indicates a durable cure – and for how long should this be monitored?

The optimum price point will need to take account of a relatively small patient population, consuming a limited number of doses, which is inherent in the single treatment paradigm. The list price of such a drug will be based, in part, on the value of future cost avoidance. This future-value issue is of great concern to payers. Will the same payer still be on board to accrue the benefits in the context of a transient patient population? This is less of an issue in national systems, where there is only one payer at any given stage of the disease progression.

In the fragmented US healthcare market, the Affordable Care Act was intended to control medical costs, in part by market competition. Individuals can switch insurance plans freely with insurance exchanges and community-based underwriting. The average tenure in an individual plan is around three years. Moreover, the health insurance industry has traditionally based its business model on a one-year underwriting time horizon.

Clearly the business question emerges: how do we value future cost avoidance and health benefits that may accrue to a party other than the original payer?

Medical economists have proposed a variety of fixes for this conundrum: reinsurance; multi-year underwriting; and cost-sharing pools. Upon deeper analysis, some variation on reinsurance appears to be the most manageable. It is a standard practice in other types of insurance, and is transparent to the patients, providers and innovators. In the end, economic success of the next wave of therapeutic innovation depends on the collaboration of, and cooperation among, all stakeholders.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, and an industry consultant with over 25 years of experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement